| (AstraZeneca) D910DC00001 / EMERALD-2 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation. | Meyers, Dr Brandon | Open to recruitment | NCT03847428 |
| (CCTG) CRC.9 / NRG-GI005 | Phase II/III Study of Circulating tumOr DNA as a Predictive BiomarRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) | Meyers, Dr Brandon | Open to recruitment | NCT04068103 |
| (Merck) MK-3475-966 | Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with advanced/Unresectable Biliary Tract Carcinoma | Kazemi, Dr Ghazaleh | Open to recruitment | NCT04003636 |
| (CCTG) CO.21 / CHALLENGE | A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE) | Goffin, Dr John | Recruitment on hold - COVID-19 | NCT00819208 |
Find a Trial
Contact Us